{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:25:10Z","timestamp":1790990710937,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["APP1003478"],"award-info":[{"award-number":["APP1003478"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"name":"University of Sydney (Australia)"},{"name":"Children's Tumor Foundation (USA)"}],"content-domain":{"domain":["thebonejournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.bone.2013.11.013","type":"journal-article","created":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T12:03:48Z","timestamp":1385035428000},"page":"151-161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Modulation of endochondral ossification by MEK inhibitors PD0325901 and AZD6244 (Selumetinib)"],"prefix":"10.1016","volume":"59","author":[{"given":"J.","family":"El-Hoss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kolind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.T.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7046-3666","authenticated-orcid":false,"given":"N.","family":"Deo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mikulec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.B.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.G.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schindeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2013.11.013_bb0005","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A comprehensive survey of Ras mutations in cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2013.11.013_bb0010","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.bone.2013.11.013_bb0015","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1158\/1535-7163.MCT-07-0162","article-title":"AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma","volume":"6","author":"Huynh","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bone.2013.11.013_bb0020","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1158\/1535-7163.MCT-10-0062","article-title":"MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo","volume":"9","author":"Henderson","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bone.2013.11.013_bb0025","series-title":"AACR meeting abstracts 2004","first-page":"1248-b-","article-title":"PK\/PD modeling of biomarker (p-ERK) response and tumor growth to PD 0325901 in a human tumor xenograft mouse model","author":"Koup","year":"2004"},{"key":"10.1016\/j.bone.2013.11.013_bb0030","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00280-010-1323-z","article-title":"Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice","volume":"67","author":"Denton","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bone.2013.11.013_bb0035","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.2007.14.4956","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers","volume":"26","author":"Adjei","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bone.2013.11.013_bb0040","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1634\/theoncologist.11-10-1121","article-title":"Bone loss and fracture risk associated with cancer therapy","volume":"11","author":"Guise","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.bone.2013.11.013_bb0045","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bjc.6690188","article-title":"A high incidence of vertebral fracture in women with breast cancer","volume":"79","author":"Kanis","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bone.2013.11.013_bb0050","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/bdrc.20048","article-title":"Transcriptional control of chondrocyte fate and differentiation","volume":"75","author":"Lefebvre","year":"2005","journal-title":"Birth Defects Res C Embryo Today"},{"key":"10.1016\/j.bone.2013.11.013_bb0055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/jcb.20652","article-title":"The control of chondrogenesis","volume":"97","author":"Goldring","year":"2006","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.bone.2013.11.013_bb0060","first-page":"S7-21","article-title":"The cell and molecular biology of fracture healing","author":"Einhorn","year":"1998","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.bone.2013.11.013_bb0065","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.semcdb.2008.07.004","article-title":"Bone remodeling during fracture repair: the cellular picture","volume":"19","author":"Schindeler","year":"2008","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.bone.2013.11.013_bb0070","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1083\/jcb.200610046","article-title":"Critical role of the extracellular signal-regulated kinase\u2013MAPK pathway in osteoblast differentiation and skeletal development","volume":"176","author":"Ge","year":"2007","journal-title":"J Cell Biol"},{"key":"10.1016\/j.bone.2013.11.013_bb0075","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1128\/MCB.01549-08","article-title":"Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis","volume":"29","author":"Matsushita","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.bone.2013.11.013_bb0080","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1128\/MCB.00617-07","article-title":"A-Raf and B-Raf are dispensable for normal endochondral bone development, and parathyroid hormone-related peptide suppresses extracellular signal-regulated kinase activation in hypertrophic chondrocytes","volume":"28","author":"Provot","year":"2008","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.bone.2013.11.013_bb0085","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/jbmr.528","article-title":"A murine model of neurofibromatosis type 1 tibial pseudarthrosis featuring proliferative fibrous tissue and osteoclast-like cells","volume":"27","author":"El-Hoss","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.11.013_bb0090","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/jor.20628","article-title":"Models of tibial fracture healing in normal and Nf1-deficient mice","volume":"26","author":"Schindeler","year":"2008","journal-title":"J Orthop Res"},{"key":"10.1016\/j.bone.2013.11.013_bb0095","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1463-1326.2009.01193.x","article-title":"Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation","volume":"12","author":"Zhang","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bone.2013.11.013_bb0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1063-4584(97)80031-3","article-title":"Variation in proteoglycan metabolism by articular chondrocytes in different joint regions is determined by post-natal mechanical loading","volume":"5","author":"Little","year":"1997","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.bone.2013.11.013_bb0105","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/art.24303","article-title":"Activation of cartilage matrix metalloproteinases by activated protein C","volume":"60","author":"Jackson","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bone.2013.11.013_bb0110","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1359\/jbmr.060603","article-title":"Ras\u2013MAPK signaling in osteogenic differentiation: friend or foe?","volume":"21","author":"Schindeler","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.11.013_bb0115","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00280-006-0323-5","article-title":"Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration","volume":"59","author":"Brown","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bone.2013.11.013_bb0120","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-06-1150","article-title":"Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1\/2 inhibitor","volume":"13","author":"Yeh","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bone.2013.11.013_bb0125","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1359\/jbmr.2002.17.10.1785","article-title":"Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix","volume":"17","author":"Higuchi","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.11.013_bb0130","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1074\/jbc.M309805200","article-title":"The MEK\u2013ERK signaling pathway is a negative regulator of cartilage-specific gene expression in embryonic limb mesenchyme","volume":"279","author":"Bobick","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bone.2013.11.013_bb0135","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/nm.2448","article-title":"Matrix-embedded cells control osteoclast formation","volume":"17","author":"Xiong","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.bone.2013.11.013_bb0140","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/jbmr.1889","article-title":"MMP driven endochondral fracture union proceeds independently of osteoclast activity","volume":"28","author":"McDonald","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.11.013_bb0145","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1242\/dev.00559","article-title":"Altered fracture repair in the absence of MMP9","volume":"130","author":"Colnot","year":"2003","journal-title":"Development"},{"key":"10.1016\/j.bone.2013.11.013_bb0150","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.bbrc.2006.12.234","article-title":"Impaired bone fracture healing in matrix metalloproteinase-13 deficient mice","volume":"354","author":"Kosaki","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bone.2013.11.013_bb0155","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1593\/neo.09398","article-title":"Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations","volume":"11","author":"Ciuffreda","year":"2009","journal-title":"Neoplasia"},{"key":"10.1016\/j.bone.2013.11.013_bb0160","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI60578","article-title":"MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors","volume":"123","author":"Jessen","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2013.11.013_bb0165","doi-asserted-by":"crossref","first-page":"18270","DOI":"10.1074\/jbc.M109.098616","article-title":"Phosphate-induced apoptosis of hypertrophic chondrocytes is associated with a decrease in mitochondrial membrane potential and is dependent upon ERK1\/2 phosphorylation","volume":"285","author":"Miedlich","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bone.2013.11.013_bb0170","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/jbmr.401","article-title":"Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice","volume":"26","author":"Ranch","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.11.013_bb0175","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.1242\/dev.01461","article-title":"Altered endochondral bone development in matrix metalloproteinase 13-deficient mice","volume":"131","author":"Stickens","year":"2004","journal-title":"Development"},{"key":"10.1016\/j.bone.2013.11.013_bb0180","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1002\/art.25002","article-title":"Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development","volume":"60","author":"Little","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bone.2013.11.013_bb0185","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1158\/1078-0432.CCR-11-1491","article-title":"Phase II, open-label, randomized trial of the MEK1\/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma","volume":"18","author":"Kirkwood","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bone.2013.11.013_bb0190","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2174\/156802607781696837","article-title":"Recent advances of MEK inhibitors and their clinical progress","volume":"7","author":"Wang","year":"2007","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bone.2013.11.013_bb0195","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00280-011-1620-1","article-title":"Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer","volume":"68","author":"Boasberg","year":"2011","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328213004742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328213004742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T17:55:45Z","timestamp":1539021345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328213004742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":39,"alternative-id":["S8756328213004742"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2013.11.013","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modulation of endochondral ossification by MEK inhibitors PD0325901 and AZD6244 (Selumetinib)","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2013.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2013 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}